These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9806064)

  • 21. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
    Casadevall A; Scharff MD
    J Exp Med; 1991 Jul; 174(1):151-60. PubMed ID: 1676047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.
    Chow SK; Casadevall A
    Vaccine; 2011 Feb; 29(10):1891-8. PubMed ID: 21238568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
    Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
    Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
    Nakouzi A; Zhang T; Oscarson S; Casadevall A
    Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
    Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A
    Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.
    Nussbaum G; Yuan R; Casadevall A; Scharff MD
    J Exp Med; 1996 Apr; 183(4):1905-9. PubMed ID: 8666947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
    Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
    J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
    Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
    Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
    Pirofski LA; Casadevall A
    Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Colombo AC; Rella A; Normile T; Joffe LS; Tavares PM; de S Araújo GR; Frases S; Orner EP; Farnoud AM; Fries BC; Sheridan B; Nimrichter L; Rodrigues ML; Del Poeta M
    mBio; 2019 Apr; 10(2):. PubMed ID: 30940711
    [No Abstract]   [Full Text] [Related]  

  • 31. Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.
    Blackstock R
    Immunology; 2003 Feb; 108(2):158-66. PubMed ID: 12562324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation.
    Jalali Z; Ng L; Singh N; Pirofski LA
    Clin Vaccine Immunol; 2006 Jul; 13(7):740-6. PubMed ID: 16829610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
    Deshaw M; Pirofski LA
    Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic Glycans Reveal Determinants of Antibody Functional Efficacy against a Fungal Pathogen.
    Crawford CJ; Guazzelli L; McConnell SA; McCabe O; d'Errico C; Greengo SD; Wear MP; Jedlicka AE; Casadevall A; Oscarson S
    ACS Infect Dis; 2024 Feb; 10(2):475-488. PubMed ID: 37856427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
    Parra C; González JM; Castañeda E; Fiorentino S
    Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies.
    Zhong Z; Pirofski LA
    Infect Immun; 1996 Sep; 64(9):3446-50. PubMed ID: 8751883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model.
    Devi SJ
    Vaccine; 1996 Jun; 14(9):841-4. PubMed ID: 8843625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antifungal activity of a human antiglucuronoxylomannan antibody.
    Zhong Z; Pirofski LA
    Clin Diagn Lab Immunol; 1998 Jan; 5(1):58-64. PubMed ID: 9455881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
    Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
    Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival.
    Blackstock R; Casadevall A
    Immunology; 1997 Nov; 92(3):334-9. PubMed ID: 9486105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.